secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001493152-21-027860
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Q3 revenue $9.5M, net loss $3.6M; new $7.5M facility, $8M term loan, $30M rights offering
--------------------------------------------------------------------------------

- Q3 revenue $9.5M (+15% YoY); loss from continuing ops $(3.5)M vs $(6.2)M; adjusted EBITDA $(1.8)M vs $(2.9)M.
- Cash collections $10.4M (2nd consecutive record quarter); DSO down 48% YoY to 59 days; cash $3.2M at Sep 30.
- Entered $7.5M Comerica revolver (matures Sep 2023) and $8M BroadOak term loan to repay private equity bridge loans.
- Proposed $30M rights offering (backstopped by 3K Limited Partnership) to fund growth; goal $100M revenue run rate by 2023.
- Expanded payor contracts: 54 commercial payors for thyroid tests; two new patents granted for ThyraMIR and PancraGEN technologies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315221027860/0001493152-21-027860-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315221027860/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-027860

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer